Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Gains from Investment Securities (2019 - 2025)

Fate Therapeutics (FATE) has disclosed Gains from Investment Securities for 11 consecutive years, with -$45000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities changed N/A year-over-year to -$45000.0, compared with a TTM value of -$987000.0 through Dec 2025, up 1.69%, and an annual FY2025 reading of -$9000.0, up 99.04% over the prior year.
  • Gains from Investment Securities was -$45000.0 for Q4 2025 at Fate Therapeutics, up from -$942000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $7.1 million in Q4 2021 and bottomed at -$942000.0 in Q3 2024.
  • Average Gains from Investment Securities over 5 years is $1.1 million, with a median of $102000.0 recorded in 2021.
  • Peak annual rise in Gains from Investment Securities hit 493.77% in 2021, while the deepest fall reached 96.98% in 2021.
  • Year by year, Gains from Investment Securities stood at $7.1 million in 2021, then plummeted by 97.68% to $164000.0 in 2022, then plummeted by 137.8% to -$62000.0 in 2023, then tumbled by 1419.35% to -$942000.0 in 2024, then soared by 95.22% to -$45000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for FATE at -$45000.0 in Q4 2025, -$942000.0 in Q3 2024, and -$62000.0 in Q4 2023.